Clinical Investigation of Intermediate‐ and High‐Purity Antihaemophilic Factor (Factor VIII) Concentrates

Abstract

S ummary . Intermediate‐ and high‐purity antibaemophilic factor (factor‐VIII) concentrates developed by the American National Red Cross (ANRC) have undergone extensive clinical investigation. When administered to severely affected haemophiliacs, the recovery in vivo and the metabolic half‐disappearance time were similar to those achieved with plasma.